Compound: hydroxyurea
SMILES: O=C(NO)N
InChIKey: VSNHCAURESNICA-UHFFFAOYSA-N
Synonyms: hydroxyurea, 127-07-1, Hydroxycarbamide, N-Hydroxyurea, Hydrea, Oxyurea, Carbamoyl oxime, Biosupressin, Carbamohydroxamic acid, Carbamohydroximic acid, Litalir, Hydroxycarbamine, Urea, hydroxy-, Onco-carbide, Droxia, Hidrix, Hydura, Carbamyl hydroxamate, Hydurea, N-Carbamoylhydroxylamine, Siklos, Hydroxicarbamidum, Hydroxylurea, Hidroxicarbamida, Xromi, Hydroxyharnstoff, Hydroxycarbamidum, N-Hydroxymocovina, Carbamohydroxyamic acid, SQ 1089, Hydroxylamine, N-carbamoyl-, Hydroxycarbamid, Oncocarbide, Idrossicarbamide, Hydroxylamine, N-(aminocarbonyl)-, SK 22591, NCI-C04831, NSC 32065, NSC-32065, DTXSID6025438, SQ-1089, AI3-51139, NSC32065, X6Q56QN5QC, DTXCID405438, CHEBI:44423, 4-03-00-00170 (Beilstein Handbook Reference), idroxicarbamide, Oxeron, Syrea, RefChem:389055, L01XX05, WR 83799, 204-821-7, 1-HYDROXYUREA, urea, N-hydroxy-, Hydreia, Litaler, Idrossicarbamide [DCIT], hydroxy urea, Hydroxyharnstoff [German], N-Hydroxymocovina [Czech], Ichthammol, Hydroxycarbamidum [INN-Latin], Hidroxicarbamida [INN-Spanish], HU, CCRIS 958, HYDROXY-UREA, MFCD00007943, N-(Aminocarbonyl)hydroxylamine, 8029-68-3, CH4N2O2, Hydroxyurea (Cytodrox), Hydroxycarbamide [INN], CHEMBL467, s1896, NCGC00015520-03, NHY, Hydroxyurea (D4), N-HYDROXY UREA, Mylocel, carbamide oxide, CAS-127-07-1, SMR000059149, Hydroxyurea (USP), Droxia (TM), Droxia (TN), Hydrea (TM), hydroxyaminomethanamide, HSDB 6887, SR-01000075919, DRG-0253, EINECS 204-821-7, HYDREA (TN), Hydroxyurea [USAN:USP], UNII-X6Q56QN5QC, BRN 1741548, Hydroxycarbamide (JAN/INN), hydroxyl urea, n-hydroxy-urea, S-phase/G-1 interface inhibitor, aminohydroxamic acid, carbamic acid oxime, Hydroxycarbamide CRS, Siklos (TN), IL-6 & Hydroxyurea, Spectrum_000909, WLN: ZVMQ, Hydrea (Bristol Meyers), Hydroxy Urea Impurity 2, HYDROXYUREA [MI], Spectrum2_000064, Spectrum3_000462, Spectrum4_000012, Spectrum5_000836, Ammonium-bitumen-sulfonate, Lopac-H-8627, HYDROXYUREA [HSDB], HYDROXYUREA [IARC], HYDROXYUREA [USAN], MolMap_000029, H 8627, HYDROXYUREA [VANDF], NCIMech_000139, Hydroxyurea, 98%, powder, SCHEMBL4004, Lopac0_000596, BSPBio_002164, HYDROXYUREA [USP-RS], KBioGR_000383, KBioSS_001389, MLS001332381, MLS001332382, MLS002153389, DivK1c_000556, HYDROXYCARBAMIDE [JAN], SPECTRUM1500344, SPBio_000247, GTPL6822, orb1310395, SCHEMBL1503487, SCHEMBL2945292, SCHEMBL3456366, HYDROXYCARBAMIDE [MART.], SCHEMBL31177136, tetratogen: inhibits ribonucleoside diphosphate reductase, HMS501L18, KBio1_000556, KBio2_001389, KBio2_003957, KBio2_006525, KBio3_001384, HYDROXYCARBAMIDE [WHO-DD], HYDROXYUREA [ORANGE BOOK], NINDS_000556, Bio1_000451, Bio1_000940, Bio1_001429, HMS1920F09, HMS2091L17, HMS2234I03, HMS3261H14, HMS3373G18, HMS3655K20, HMS3869C03, HMS5080E21, NCI C04831, Pharmakon1600-01500344, HYDROXYCARBAMIDE [EMA EPAR], HYDROXYUREA [USP MONOGRAPH], ichthyol, ichthammol, PSSO, DSSO, ALBB-028465, HY-B0313, STR02555, Tox21_110168, Tox21_300319, Tox21_500596, BBL009928, BDBM50017811, CCG-35236, EBC-03024, MSK163509, NSC757072, STL145898, AKOS005716276, AKOS006222547, Tox21_110168_1, DB01005, FH09735, HYDROXYCARBAMIDE [EP MONOGRAPH], LP00596, NSC-757072, SDCCGSBI-0050578.P006, IDI1_000556, NCGC00015520-01, NCGC00015520-02, NCGC00015520-04, NCGC00015520-05, NCGC00015520-06, NCGC00015520-07, NCGC00015520-08, NCGC00015520-09, NCGC00015520-10, NCGC00015520-11, NCGC00015520-20, NCGC00093974-01, NCGC00093974-02, NCGC00093974-03, NCGC00093974-04, NCGC00093974-05, NCGC00254007-01, NCGC00261281-01, AC-22674, NCI60_002773, SBI-0050578.P004, DB-041849, EU-0100596, H0310, NS00002419, SW218071-2, EN300-82775, A10546, C07044, D00341, Hydroxyurea, Vetec(TM) reagent grade, >=98%, AB00052018-09, AB00052018-10, AB00052018_11, AB00052018_12, F043351, Q212272, SR-01000075919-1, SR-01000075919-3, SR-01000075919-8, BRD-K51747290-001-12-3, BRD-K51747290-001-13-1, BRD-K51747290-001-15-6, E0723DBA-5AF3-49D1-B5F6-59420AB87AC9, F8880-0905, Z1203577934, Hydroxycarbamide, European Pharmacopoeia (EP) Reference Standard, Hydroxyurea, United States Pharmacopeia (USP) Reference Standard
Theoretical properties:
molecular_formula: CH4N2O2
molecular_weight: 76.055 g/mol
exact_mass: 76.027277375 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 3
hydrogen_bond_acceptor_count: 2
rotatable_bond_count: 0
heavy_atom_count: 5
topological_polar_surface_area: 75.4 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
physical_state: Needles from alcohol
color: Needles from alcohol
boiling_point: Decomposes (NTP, 1992)
melting_point: 291 to 295 °F (decomposes) (NTP, 1992)
solubility: greater than or equal to 100 mg/mL at 70 °F (NTP, 1992)
Descriptions:
pubchem: Hydroxyurea can cause developmental toxicity according to state or federal government labeling requirements.
chebi: A member of the class of ureas that is urea in which one of the hydrogens is replaced by a hydroxy group. An antineoplastic used in the treatment of chronic myeloid leukaemia as well as for sickle-cell disease.
chembl: HYDROXYUREA is a small molecule listed in the ChEMBL database and has reached clinical trial phase 4.0.
wikipedia: Hydroxycarbamide, also known as hydroxyurea, is an antimetabolite medication used in sickle-cell disease, essential thrombocythemia, chronic myelogenous leukemia, polycythemia vera, and cervical cancer. In sickle-cells disease it increases fetal hemoglobin and decreases the number of attacks. It is taken by mouth.
Common side effects include bone marrow suppression, fevers, loss of appetite, psychiatric problems, shortness of breath, and headaches. There is also concern that it increases the risk of later cancer. Use during pregnancy is typically harmful to the fetus. Hydroxycarbamide is in the antineoplastic family of medications. It is believed to work by blocking the making of DNA.
Hydroxycarbamide was approved for medical use in the United States in 1967. It is on the World Health Organization's List of Essential Medicines. Hydroxycarbamide is available as a generic medication.